Piperidine → Glycyl-phenylalanyl-glycine

HRID 39265

반응식

HRID 39265 반응식
C1C2C(COC([NH:18][CH2:19][C:20]([NH:22][C@H:23]([C:31]([NH:33][CH2:34][C:35]([OH:37])=[O:36])=[O:32])[CH2:24][C:25]3[CH:30]=[CH:29][CH:28]=[CH:27][CH:26]=3)=[O:21])=O)C3C(=CC=CC=3)C=2C=CC=1.N1CCCCC1>CN(C=O)C>[NH2:18][CH2:19][C:20]([NH:22][C@H:23]([C:31]([NH:33][CH2:34][C:35]([OH:37])=[O:36])=[O:32])[CH2:24][C:25]1[CH:30]=[CH:29][CH:28]=[CH:27][CH:26]=1)=[O:21]

참가 물질

4

반응물 2

HCID 8082PiperidineHCID 15222489N-Fmoc-glycyl-L-phenylalanyl-glycine

생성물 1

HCID 6992441Glycyl-phenylalanyl-glycine

시약·촉매·용매 1

HCID 6228Dimethylformamide용매

실험 절차

Fmoc-protected tripeptide 74 (546 mg, 0.98 mmol) was treated with a 5% v/v solution of piperidine in DMF (5 mL). After stirring for 45 min, the reaction mixture was concentrated to dryness. The crude material was used for the next step without purification.

후처리

  1. concentrationthe reaction mixture was concentrated to dryness
  2. customThe crude material was used for the next step without purification

출처 및 근거

ORD 기록
ord-7e66b13904154ebcbe524b75757fe2f1
출처 데이터셋
uspto-grants-2013_09
특허 번호
US08524691B2

연결된 노트

불러오는 중…